Skip to main content

Table 2 Logistic regression for risk factors for adverse pathological outcomes

From: Free testosterone value before radical prostatectomy is related to oncologic outcomes and post-operative erectile function

Variables pT3 Gleason 8 or higher
  OR 95%CI p value OR 95%CI p value
TT (normal vs low) 1.017 0.479–2.159 0.965 0.484 0.237–0.985 0.045*
FT (normal vs low) 0.587 0.374–0.921 0.020* 0.456 0.249-0.835 0.011*
Age (continuous) 1.006 0.979–1.034 0.665 1.006 0.979–1.003 0.677
BMI (continuous) 1.016 0.960–1.076 0.581 1.014 0.960–1.072 0.607
Diabetes (presence vs absence) 1.243 0.719–2.149 0.436 0.970 0.573–1.641 0.909
Hypertension (presence vs absence) 0.855 0.472–1.549 0.605 1.087 0.629–1.878 0.765
Coronary heart disease (presence vs absence) 1.203 0.624–2.322 0.581 1.279 0.683–2.395 0.443
Smoke (presence vs absence) 1.280 0.723–2.266 0.397 1.400 0.825–2.376 0.212
Alcohol (presence vs absence) 0.763 0.471–1.236 0.272 1.428 0.924–2.208 0.109
PSA (≥10 ng/ml vs < 10 ng/ml) 1.007 0.644–1.575 0.975 1.829 1.195–2.800 0.005*
Proportion of free-PSA (≥ 0.16 vs < 0.16) 0.851 0.540–1.340 0.486 1.030 0.664–1.599 0.894
Clinical Tumor stage (T2a vs T3) 0.057 0.021–0.153 < 0.001* 0.439 0.212-0.909 0.027*
Clinical (T2b vs T3) 0.059 0.029–0.120 < 0.001* 0.454 0.258-0.800 0.006*
Clinical (T2c vs T3) 0.474 0.299–0.750 0.001* 0.840 0.513-1.374 0.487
Biopsy Gleason Score (6 vs 8 or higher) 0.289 0.149–0.562 < 0.001* 0.179 0.093-0.344 < 0.001*
Biopsy Gleason Score (7 vs 8 or higher) 0.800 0.500–1.279 0.351 0.723 0.467–1.121 0.148
  1. OR odds ratio; CI confidence interval; TT total testosterone; FT free testosterone; PSA prostate-specific antigen; BMI body mass index; PSM positive surgical margin
  2. p value of less than 0.05 are in boldface
  3. *Statistically significant